
News|Articles|October 1, 2008
FDA Pipeline preview, October 2008 (vernakalant, doripenem, custirsen, droxidopa, amrubicin, dronedarone, imatinib)
Recent FDA action (through October 2008) related to vernakalant, doripenem, custirsen, droxidopa, amrubicin, dronedarone, and imatinib.
Advertisement
Approvable designation*
Complete responses*
Fast-track designations
Orphan drug designations
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Neffy’s first year: $72.2m in sales, 10,000 schools and broadening payer access
2
Centanafadine hits primary and key secondary endpoints in ADHD phase 3b trial
3
Brukinsa/rituximab cuts progression risk 43% in mantle cell lymphoma
4
New study confirms benefits of GLP-1 drugs in patients with PAD
5
































